ACRS Aclaris Therapeutics, Inc.

32.23
0  -1%
Previous Close 32.43
Open 32.41
Price To book 4.99
Market Cap 840.82M
Shares 26,088,000
Volume 71,547
Short Ratio 6.90
Av. Daily Volume 215,618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ATI-50002
Patchy alopecia areata
Phase 2 trial to be initiated 2H 2017.
ATI-50001
Alopecia totalis and alopecia universalis
NDA filing announced February 27, 2017.
A-101
Seborrheic keratosis (SK)
Phase 2 data released August 2016. Plans to initiate two Phase 2 trials in mid-2017.
A-101
Common warts (verruca vulgaris)